BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20517534)

  • 1. Mifamurtide in osteosarcoma--a practical review.
    Anderson PM; Tomaras M; McConnell K
    Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
    Meyers PA; Chou AJ
    Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
    Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
    Meyers PA
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1035-49. PubMed ID: 19671023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
    Ando K; Mori K; Corradini N; Redini F; Heymann D
    Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mifamurtide: a review of its use in the treatment of osteosarcoma.
    Frampton JE
    Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
    Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
    Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
    Kleinerman ES; Maeda M; Jaffe N
    Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifamurtide: osteosarcoma: ineffective and harmful.
    Prescrire Int; 2011 Apr; 20(115):89. PubMed ID: 21648206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis.
    Johal S; Ralston S; Knight C
    Value Health; 2013 Dec; 16(8):1123-32. PubMed ID: 24326165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of mifamurtide in addition to standard chemotherapy for high-grade osteosarcoma: a systematic review.
    Jimmy R; Stern C; Lisy K; White S
    JBI Database System Rev Implement Rep; 2017 Aug; 15(8):2113-2152. PubMed ID: 28800058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
    Anderson P
    Future Oncol; 2006 Jun; 2(3):333-43. PubMed ID: 16787112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [L-MTP-PE--a potential antineoplastic agent].
    Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
    Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
    Mori K; Ando K; Heymann D
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):151-9. PubMed ID: 18279055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience.
    Taçyıldız N; Unal E; Dinçaslan H; Çakmak HM; Köse K; Tanyıldız G; Kartal Ö
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):715-720. PubMed ID: 32212798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal MTP-PE.
    Gano JB; Kleinerman ES
    J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
    [No Abstract]   [Full Text] [Related]  

  • 19. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.
    Nardin A; Lefebvre ML; Labroquère K; Faure O; Abastado JP
    Curr Cancer Drug Targets; 2006 Mar; 6(2):123-33. PubMed ID: 16529542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.